Abstract
Background: Anticardiolipin antibodies of the immunoglobulin G isotype (IgG aCL) have been suggested as risk factor for arterial and venous thrombosis. No conclusive data in patients with coronary artery disease (CAD) do exist. We investigate the risk of recurrent CAD according to the presence of IgG aCL. Methods: We performed a systematic review and meta-analysis to evaluate the risk of recurrent major adverse cardiac events (MACE) associated with the presence of IgG aCL in patients with CAD. MEDLINE and Cochrane databases were searched. We conducted a meta-analysis of the relative risk (RR) both at 12 and 24 months. Results: We included 11 eligible studies with a total of 2425 patients, 283 IgG aCL+ and 2142 IgG aCL-. The prevalence of IgG aCL+ ranged from 6.1% to 43.3%. A total of 341 cardiac events were reported: 71 (25.1%) in IgG aCL+ and 270 (12.6%) in IgG aCL- patients. We found an increased risk of recurrent MACE in patients with high IgG aCL both at 12 (RR 2.17, 2.5–97.5%CI, 1.54–3.00) and 24 months (RR 2.11, 2.5–97.5%CI, 1.62–2.66). This association was even stronger in patients with juvenile CAD (i.e. <50 years) at both 12 (RR 3.21, 2.5–97.5%CI, 1.74–5.41) and 24 months (RR 3.24, 2.5–97.5%CI, 1.84–5.21). Conclusion: Patients with CAD and elevated IgG aCL have a doubled risk of recurrent MACE at 12 and 24 months. The presence of aCL should be suspected in patients with recurrent CAD events or in patients with juvenile CAD.
| Original language | English |
|---|---|
| Journal | Autoimmunity reviews |
| DOIs | |
| Publication status | Published - 1 Jan 2019 |
Fingerprint
Keywords
- Anticardiolipin
- Antiphospholipid
- Cardiovascular events
- Myocardial infarction
Cite this
}
Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis. / Pastori, Daniele; Bucci, Tommaso; Triggiani, Massimo; Ames, Paul R.J.; Parrotto, Sandro; Violi, Francesco; Pignatelli, Pasquale; Farcomeni, Alessio.
In: Autoimmunity reviews, 01.01.2019.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis
AU - Pastori, Daniele
AU - Bucci, Tommaso
AU - Triggiani, Massimo
AU - Ames, Paul R.J.
AU - Parrotto, Sandro
AU - Violi, Francesco
AU - Pignatelli, Pasquale
AU - Farcomeni, Alessio
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Anticardiolipin antibodies of the immunoglobulin G isotype (IgG aCL) have been suggested as risk factor for arterial and venous thrombosis. No conclusive data in patients with coronary artery disease (CAD) do exist. We investigate the risk of recurrent CAD according to the presence of IgG aCL. Methods: We performed a systematic review and meta-analysis to evaluate the risk of recurrent major adverse cardiac events (MACE) associated with the presence of IgG aCL in patients with CAD. MEDLINE and Cochrane databases were searched. We conducted a meta-analysis of the relative risk (RR) both at 12 and 24 months. Results: We included 11 eligible studies with a total of 2425 patients, 283 IgG aCL+ and 2142 IgG aCL-. The prevalence of IgG aCL+ ranged from 6.1% to 43.3%. A total of 341 cardiac events were reported: 71 (25.1%) in IgG aCL+ and 270 (12.6%) in IgG aCL- patients. We found an increased risk of recurrent MACE in patients with high IgG aCL both at 12 (RR 2.17, 2.5–97.5%CI, 1.54–3.00) and 24 months (RR 2.11, 2.5–97.5%CI, 1.62–2.66). This association was even stronger in patients with juvenile CAD (i.e. <50 years) at both 12 (RR 3.21, 2.5–97.5%CI, 1.74–5.41) and 24 months (RR 3.24, 2.5–97.5%CI, 1.84–5.21). Conclusion: Patients with CAD and elevated IgG aCL have a doubled risk of recurrent MACE at 12 and 24 months. The presence of aCL should be suspected in patients with recurrent CAD events or in patients with juvenile CAD.
AB - Background: Anticardiolipin antibodies of the immunoglobulin G isotype (IgG aCL) have been suggested as risk factor for arterial and venous thrombosis. No conclusive data in patients with coronary artery disease (CAD) do exist. We investigate the risk of recurrent CAD according to the presence of IgG aCL. Methods: We performed a systematic review and meta-analysis to evaluate the risk of recurrent major adverse cardiac events (MACE) associated with the presence of IgG aCL in patients with CAD. MEDLINE and Cochrane databases were searched. We conducted a meta-analysis of the relative risk (RR) both at 12 and 24 months. Results: We included 11 eligible studies with a total of 2425 patients, 283 IgG aCL+ and 2142 IgG aCL-. The prevalence of IgG aCL+ ranged from 6.1% to 43.3%. A total of 341 cardiac events were reported: 71 (25.1%) in IgG aCL+ and 270 (12.6%) in IgG aCL- patients. We found an increased risk of recurrent MACE in patients with high IgG aCL both at 12 (RR 2.17, 2.5–97.5%CI, 1.54–3.00) and 24 months (RR 2.11, 2.5–97.5%CI, 1.62–2.66). This association was even stronger in patients with juvenile CAD (i.e. <50 years) at both 12 (RR 3.21, 2.5–97.5%CI, 1.74–5.41) and 24 months (RR 3.24, 2.5–97.5%CI, 1.84–5.21). Conclusion: Patients with CAD and elevated IgG aCL have a doubled risk of recurrent MACE at 12 and 24 months. The presence of aCL should be suspected in patients with recurrent CAD events or in patients with juvenile CAD.
KW - Anticardiolipin
KW - Antiphospholipid
KW - Cardiovascular events
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85062293962&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2019.03.005
DO - 10.1016/j.autrev.2019.03.005
M3 - Review article
JO - Autoimmunity reviews
JF - Autoimmunity reviews
SN - 1568-9972
ER -